Summary
Biogel P-30 filtration of plasma from Type 1 (insulin-dependent) diabetic patients and normal subjects in basal state and after an oral glucose load was assayed with a C-terminal (30 K) and a glucagon-like immunoreactivity-cross-reacting antiserum (R8). Up to four immunoreactive peaks of approximate molecular sizes of >20,000 (fraction I), 9000 (fraction II), 3500 (fraction III) and 2000 (fraction IV) were detected with the two antisera in both groups. In the basal state, the only significant difference observed between both groups was a higher R8-reactivity in fraction II in the group of diabetic patients, although the R 8 minus 30 K values for this fraction did not show a significant difference between both groups. After glucose the only significant differences were an increase of R8-reactivity in fraction II in both groups (p<0.01) and a decrease of 30 K-reactivity in fraction III (IRG3500) in normal subjects (p<0.05). In seven out of 12 diabetic patients, 30 K-reactivity in fraction II (IRG9000) and III (IRG3500) increased above their basal values. The gut-glucagon-like immunoreactivity response to oral glucose (ΔR8-Δ30 K values in fraction II) was similar in both the diabetic and normal subjects. These results indicate that (1) the paradoxical rise in plasma immunoreactive glucagon after oral glucose in diabetic patients may be due to an increase of both IRG3500 and/or IRG9000, (2) the gut-glucagon-like immunoreactivity released during glucose absorption has a molecular weight of approximately 9000, and (3) no differences in plasma gut-glucagonlike immunoreactivity were observed in Type 1 diabetic patients when compared with normal subjects, either in the basal state or after glucose ingestion.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Muller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 283: 109–115
Buchanan KD, McCarroll AM (1972) Abnormalities of glucagon metabolism in untreated diabetes mellitus. Lancet 2: 1394–1395
Heding LG, Rasmussen SM (1972) Determination of pancreatic and gut glucagon-like immunoreactivity in normal and diabetic subjects. Diabetologia 8: 408–411
Day JL, Anderson JA (1973) Abnormalities of glucagon metabolism in diabetes mellitus. Clin Endocrinol 2: 211–217
Kurahachi H, Seino Y, Ikeda M, Sakurai H, Yoshimi T, Imura H (1977) Insuppressibility of plasma glucagon by orally or intravenously administered glucose in diabetes mellitus. Endocrinol Japon 24 (5): 413–419
Aydin I, Raskin P, Unger RH (1977) The effect of short-term intravenous insulin administration on the glucagon response to a carbohydrate meal in adult onset and juvenile type diabetes. Diabetologia 13: 629–636
Matsuyama T, Hoffman WH, Dunbar JC, Foà NL, Fòa PP (1975) Glucose, insulin, pancreatic glucagon and glucagon-like immunoreactive materials in the plasma of normal and diabetic children. Effect of the initial insulin treatment. Horm Metab Res 7: 452–456
Valverde I (1983) Heterogeneity of circulating glucagon and glucagon-like immunoreactivity. In: Lefebvre PJ (ed) Glucagon I. Handbook of experimental pharmacology 66: I, Springer, Berlin Heidelberg New York Tokyo, pp 223–244
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Faloona GR, Unger RH (1974) Glucagon. In: Jaffe BM, Behrman HR (eds) Methods of hormone radioimmunoassay. Academic Press, New York, pp 317–320
Jörgensen KH, Larsen UD (1972) Purification of 125I-glucagon by anion exchange chromatography. Horm Metab Res 4: 223–224
Valverde I, Ghiglione M, Matesanz R, Casado S (1979) Chromatographic pattern of gut glucagon-like immunoreactivity (GLI) in plasma before and during glucose absorption. Horm Metab Res 11: 343–346
Faloona GR (1972) The structure-function relationships of pancreatic glucagon. In: Lefebvre PJ, Unger RH (eds) Glucagon: molecular physiology, clinical and therapeutic implications. Pergamon Press, Oxford, New York, Toronto, Sydney, Braunschweig, pp 201–204
Herbert V, Lau K-S, Gottlieb CW, Bleicher SJ (1965) Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25: 1375–1384
Valverde I, Villanueva ML, Lozano I, Marco J (1974) Presence of glucagon immunoreactivity in the globulin fraction of human plasma (“big plasma glucagon”). J Clin Endocrinol Metab 39: 1090–1098
Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM (1970) Studies of pancreatic alpha-cell function in normal and diabetic subjects. J Clin Invest 49: 837–848
Rigopoulou D, Valverde I, Marco J, Faloona G, Unger RH (1970) Large glucagon immunoreactivity in extracts of pancreas. J Biol Chem 245: 496–501
Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC (1983) Exon duplication and divergence in the human preproglucagon gene. Nature 304: 368–371
Jaspan JB, Rubenstein AH (1977) Circulating glucagon. Plasma profiles and metabolism in health and disease. Diabetes 26: 887–904
Valverde I, Villanueva ML, Lozano I, Roman D, Diaz-Fierros M, Marco J (1973) Chromatographic pattern of human intestinal glucagon-like immunoreactivity. J Clin Endocrinol Metab 36: 185–187
Valverde I, Rigopoulou D, Marco J, Faloona GR, Unger RH (1970) Characterization of glucagon-like immunoreactivity. Diabetes 19: 614–623
Tager HS, Markese J (1979) Intestinal and pancreatic glucagonlike polypeptides. Evidence for identity of higher molecular weight forms. J Biol Chem 254: 2229–2233
Thim L, Moody AJ (1981) The primary structure of porcine glicentin (proglucagon). Regul Peptides 2: 139–150
Rovira A, López-Novoa JM, Zubiaur M, Matesanz R, Ghiglione M, Pascual JM, Valverde I (1982) Renal metabolism of gut glucagon like immunoreactivity. Endocrinology 110: 2030–2036
Marco J, Baroja IM, Diaz-Fierros M, Villanueva ML, Valverde I (1972) Relationship between insulin and gut glucagon-like immunoreactivity secretion in normal and gastrectomized subjects. J Clin Endocrinol Metab 34: 188–191
Shima K, Kuroda K, Matsuyama T, Tarni S, Nishikawa M (1972) Plasma glucagon and insulin responses to various sugars in gastrectomized subjects. Proc Soc Exp Biol Med 139: 1042–1048
Bloom SR, Royston C, Thomson J (1972) Enteroglucagon release in the dumping syndrome. Lancet 2: 788–791
Bataille D, Gespach C, Tatemoto K, Marie J-C, Coudray A-M, Rosselin G, Mutt V (1981) Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 2 (Suppl 2): 41–44
Moody AJ, Sundby F, Jacobsen H (1978) The tissue distribution and plasma levels of glicentin (gut GLI-I). Scand J Gastroenterology 13 (Suppl 49): 127 (Abstract)
Holst JJ (1982) Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33–69) of glicentin. Biochem J 207: 381–388
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rovira, A., Garrote, F.J., Pascual, J.M. et al. Plasma glucagon and glucagon-like immunoreactive components in Type 1 (insulin-dependent) diabetic patients and normal subjects before and after an oral glucose load. Diabetologia 28, 80–86 (1985). https://doi.org/10.1007/BF00279920
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00279920